NCT07195227
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07195227
Title Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer (CADILLAC)
Acronym CADILLAC
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedSIR
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP | DEU


No variant requirements are available.